Anti-VEGF in Real-world

Sponsor
Wenbin Wei
Study ID
NCT05222633
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
35 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • Ranibizumab — DRUG
    Ranibizumab 0.5mg/0.05ml intravitreal injection
  • Aflibercept — DRUG
    Aflibercept 2.0mg/0.05ml intravitreal injection
  • Conbercept — DRUG
    Conbercept 0.5mg/0.05ml intravitreal injection

Study Details

Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-vascular endothelial growth factor therapy drugs. In the current study, the primary aim is to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting.

Key Dates

Start date
Jan 1, 2022
Status verified
Feb 2022
Primary completion
Jan 1, 2023
Completion
May 1, 2023

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: Neovascular age-related macular edema
    Patients with new-onset and recurrent Neovascular age-related macular edema.
  • Arm: Diabetic macula edema
    Patients with new-onset and recurrent diabetic macula edema
  • Arm: Non-proliferative diabetic retinopathy/proliferative diabetic retinopathy
    Patients with new-onset and recurrent non-proliferative diabetic retinopathy/proliferative diabetic retinopathy
  • Arm: Retinal vein occlusions
    Patients with new-onset and recurrent retinal vein occlusions
  • Arm: Choroidal neovascularization
    Patients with new-onset and recurrent choroidal neovascularization

Primary Outcome Measure

Visual acuity [ Time Frame: 1 year ]

Central Contacts

Related Studies